HealthCap
Organization
Investments
Series A, Lead, Sep 17, 2026
Series B, Jul 23, 2025
Series C, $5.1M, Feb 1, 2019
Series B, $11.5M, Mar 1, 2016
Sources: businesswire.com, femtechinsider.com, sec.gov
Named in competing interests
Metabolic, enterohepatic and gut microbial effects of atorvastatin in healthy men
Consulting or advice, Grants or research support, Board or leadership role, Mar 9, 2026
Sources: pubmed.ncbi.nlm.nih.gov